{"organizations": [], "uuid": "d1aa30f50dfcaa3af78fa84927650f28af07e8dd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sellas-life-sciences-announces-pos/brief-sellas-life-sciences-announces-positive-interim-data-from-phase-2b-neuvax-clinical-trial-in-combination-with-herceptin-idUSASC09UGP", "country": "US", "domain_rank": 408, "title": "BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-02T15:51:00.000+03:00", "replies_count": 0, "uuid": "d1aa30f50dfcaa3af78fa84927650f28af07e8dd"}, "author": "", "url": "https://www.reuters.com/article/brief-sellas-life-sciences-announces-pos/brief-sellas-life-sciences-announces-positive-interim-data-from-phase-2b-neuvax-clinical-trial-in-combination-with-herceptin-idUSASC09UGP", "ord_in_thread": 0, "title": "BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-sellas life sciences announces positive interim data from phase", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "sellas life sciences group inc", "sentiment": "none"}, {"name": "neuvax clinical trial in combination with herceptin reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2, 2018 / 12:54 PM / in 7 minutes BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin Reuters Staff 1 Min Read \nApril 2 (Reuters) - Sellas Life Sciences Group Inc: \n* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS \n* CLINICALLY AND STATISTICALLY SIGNIFICANT EFFICACY IN TRIPLE NEGATIVE BREAST CANCER \n* CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DIFFERENCE WAS FOUND BETWEEN TWO ARMS IN COHORT OF PATIENTS​ \n* ‍ADDITION OF NEUVAX TO HERCEPTIN DID NOT RESULT IN ANY ADDITIONAL CARDIOTOXICITY COMPARED TO HERCEPTIN ALONE​ * TOLERATED​ \n* SPECIFIED INTERIM ANALYSIS SHOWED AN ADVERSE EVENT PROFILE WITH NO NOTABLE DIFFERENCES BETWEEN TREATMENT ARMS​ \n* ‍DSMB RECOMMENDED TO SEEK REGULATORY GUIDANCE BY FDA FOR FURTHER DEVELOPMENT OF COMBINATION OF NEUVAX + HERCEPTIN IN TNBC​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-02T15:51:00.000+03:00", "crawled": "2018-04-02T16:04:07.010+03:00", "highlightTitle": ""}